Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes.

S M Weber1, W R Jarnagin, D Klimstra

  • 1Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Journal of the American College of Surgeons
|October 5, 2001
PubMed
Summary

Surgical resection offers improved survival for intrahepatic cholangiocarcinoma (IHC), a rare bile duct cancer. However, recurrence is common, with local or regional spread guiding future adjuvant therapy strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas.

Oncogene·2013
Same author

Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation.

Annals of surgical oncology·2012
Same author

Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.

Cancer gene therapy·2003
Same author

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Genes & development·2001
Same author

Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Annals of surgery·2001
Same author

A historic perspective of liver surgery for tumors at the end of the millennium.

Journal of the American College of Surgeons·2001

Area of Science:

  • Hepatobiliary Surgery
  • Surgical Oncology
  • Gastroenterology

Background:

  • Intrahepatic cholangiocarcinoma (IHC) is a rare primary liver cancer originating from bile ducts.
  • Surgical resection is the most effective curative treatment for IHC.
  • Limited data exists on the resectability, outcomes, and recurrence patterns of IHC.

Purpose of the Study:

  • To evaluate the resectability rates, survival outcomes, and recurrence patterns of patients with intrahepatic cholangiocarcinoma.
  • To identify factors influencing survival and recurrence after surgical resection for IHC.

Main Methods:

  • A prospective database was used to identify 53 patients with pure IHC between March 1992 and September 2000.
  • Patients underwent surgical exploration, and data on demographics, tumor characteristics, and outcomes were analyzed.

Related Experiment Videos

  • Exclusion criteria included mixed hepatocellular and cholangiocarcinoma tumors.

    • Main Results:

    • The overall resectability rate was 62% (33 of 53 patients).
    • Median survival was significantly longer for resected patients (37.4 months) compared to biopsy-only patients (11.6 months).
    • Predictive factors for poor survival included vascular invasion, positive margins, and multiple tumors. Recurrence occurred in 61% of resected patients, with local/regional sites being most common.

    Conclusions:

    • Complete resection of intrahepatic cholangiocarcinoma improves survival but is associated with a high rate of recurrence.
    • Factors like multiple tumors, tumor size, and vascular invasion predict recurrence.
    • Understanding recurrence patterns, predominantly local/regional, can inform future adjuvant therapy strategies for IHC.